Donor Funding Drives $15M Initiative Supporting 62 Researchers Focused on Alzheimer’s, Macular Degeneration, and Glaucoma The BrightFocus Foundation has announced a major new investment of $15.2 million in research grants aimed at advancing scientific discovery in three of the most…
U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus Genentech, a member of the Roche Group, has announced a major regulatory milestone in its efforts to expand treatment options for autoimmune diseases.…
Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision oncology subsidiary, Ignite Proteomics. The subsidiary has been featured in…
Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it will showcase its proprietary nPulse™ platform and present new clinical…
Akamis Bio Reports Promising Early Findings from Phase 1b FORTRESS Trial of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer Akamis Bio, a biotechnology company focused on transforming the treatment landscape for colorectal cancer, has reported encouraging early clinical data from…
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season Merck & Co.—known as MSD outside the United States and Canada—has announced a major regulatory…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At the ESCMID Global 2026, Bruker Corporation unveiled a wide-ranging set of portfolio enhancements spanning microbial identification, outbreak surveillance, and reflex next-generation sequencing (NGS) workflows. These updates…
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home…
Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S. launch of Sdamlo™ (amlodipine for…
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Yvonne McGrath,…
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public…
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced that initial patients have been…